Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452919 | 0.84 | ACE (0.47) | ACE2ACE | |
| SCHEMBL4446606 | 0.84 | ITGB3 (0.39) | ROCK2ACE2ACE | |
| SCHEMBL6798893 | 0.81 | CHRNA1 (0.42) | ACE2OPRD1 | |
| SCHEMBL6801466 | 0.80 | GRIA1 (0.42) | ACE2ACEOPRD1 | |
| SCHEMBL6802332 | 0.80 | CTSS (0.51) | ROCK2ACE2F2ACE | |
| SCHEMBL6798801 | 0.79 | ACE (0.43) | ACE2ACEITGA4ITGB1 | |
| SCHEMBL6804307 | 0.79 | KMT2A (0.49) | ACE2ACE | |
| SCHEMBL6803819 | 0.79 | ITGB3 (0.37) | ROCK2ACE | |
| SCHEMBL6801711 | 0.79 | CTSS (0.48) | ROCK2ACE2ACE | |
| SCHEMBL4454262 | 0.78 | ITGB3 (0.42) | ACE2ACELNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | ROCK2 2088/4885ACE2 507/4885F2 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.